Safety assessment of Osilodrostat: The adverse event analysis based on FAERS database by means of disproportionality analysis
PLOS One · 07.08.2025 · 20 (8) · e0329088
DOI: 10.1371/journal.pone.0329088 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 07.08.2025. Verfasst von Lijun Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, the Second Affiliated Hospital, University of South China, Hengyang, China. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Cushing Syndrome, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hunan Province.
Abstract (Originalsprache)
Background
Osilodrostat is a medication recently approved for the treatment of Cushing’s syndrome. However, there is a current dearth of large-scale studies on the adverse events associated with Osilodrostat. Consequently, this study aims to comprehensively evaluate these adverse events using data from the FDA Adverse Event Reporting System (FAERS).
Methods
A disproportionality analysis was utilized to identify signals of adverse events linked to Osilodrostat. Furthermore, a Weibull distribution analysis was conducted to evaluate the temporal evolution of adverse events, and subgroup analyses were performed. The Wilcoxon test was applied to investigate differences in the temporal patterns of adverse events across different genders.
Results
A total of 1,078 cases related to Osilodrostat were identified, including 3,744 adverse events. The most frequent and severe signals of adverse events were investigations, off-label use, fatigue, nausea, and adrenal insufficiency. The median time to onset of adverse events related to Osilodrostat was 52 days after starting the medication. There was a gender difference in the median time to onset of adverse events, with a median of 15 days for males and 34 days for females.
Conclusion
This study provides a comprehensive evaluation of adverse events related to Osilodrostat, confirming some known side effects and revealing other potential risks. This information offers valuable insights for the clinical application of Osilodrostat.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Pharmacy, the Second Affiliated Hospital, University of South China, Hengyang, China.
- Hengyang Medical School, University of South China, Hengyang, Hunan, China.
- Hunan Provincial Key Clinical Laboratory of Basic and Clinical Pharmacologlcal Research of Gastnointestinal cancer, the Second Affiliated Hospital, University of South China, Hengyang, Hunan, China.
- Department of Nursing, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
ORCID-Profile: Lijun Li
Förderung
- Natural Science Foundation of Hunan Province
Zitieren
APA
Li, L., & Zhao, W. (2025). Safety assessment of Osilodrostat: The adverse event analysis based on FAERS database by means of disproportionality analysis. PLOS One, 20(8), e0329088. https://doi.org/10.1371/journal.pone.0329088
Vancouver
Li L, Zhao W. Safety assessment of Osilodrostat: The adverse event analysis based on FAERS database by means of disproportionality analysis. PLOS One. 2025;20(8):e0329088. doi:10.1371/journal.pone.0329088
BibTeX
@article{Li2025,
author = {Li, Lijun and Zhao, Wanchen},
title = {Safety assessment of Osilodrostat: The adverse event analysis based on FAERS database by means of disproportionality analysis},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {8},
pages = {e0329088},
doi = {10.1371/journal.pone.0329088}
}
EUVIMED